Innovation1 Biotech Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVBT research report →
About the company
Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily engaged in creating modified botanical Schedule 1 molecules for use within the United States. The firm's pipeline encompasses five entirely synthetic, proprietary prodrugs that are currently in preclinical development, each designed to tackle a unique set of medical conditions.
- CEO
- Francis Knuettel
- IPO
- 2017
- Employees
- 1
- HQ
- Somerville, NY, US
Price Chart
- Market Cap
- $4.49K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2074.16%
- ROIC
- 42.71%
- Revenue
- $0 · 0.00%
- Net Income
- $-5,988,000 · 85.35%
- EPS
- $-0.70 · 74.36%
- Op Income
- $-1,367,000
- FCF YoY
- 80.19%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 5.83
- Avg Volume
- 169.86
Get TickerSpark's AI analysis on IVBT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 23, 25 | Knipper Samuel J | other | 0 |
| Nov 1, 24 | Francis Knuettel II | other | 1,023,511,950 |
Our IVBT coverage
Recent articles, reports, and earnings notes.
No research on IVBT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IVBT report →Similar companies
Peers in the same neighborhood.